2100 WHARTON STREET, PITTSBURGH, PA
Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Investor Presentation
Director Resignation - Kirti Ganorkar Steps Down from Board
Announces Third Quarter 2025 Financial and Operating Results
Other Events
Announces Second Quarter 2025 Financial and Operating Results
Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus Filed Pursuant to Rule 424(b)(2)
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence
S-1MEF